Zidovudine-induced anemia

Zidovudine-induced anemia is an acquired hematologic toxicity occurring in individuals undergoing antiretroviral therapy with the nucleoside reverse transcriptase inhibitor zidovudine, most commonly in the context of human immunodeficiency virus (HIV) infection

Zidovudine-induced anemia is an acquired hematologic toxicity occurring in individuals undergoing antiretroviral therapy with the nucleoside reverse transcriptase inhibitor zidovudine, most commonly in the context of human immunodeficiency virus (HIV) infection It is characterized by dose- and duration-dependent bone marrow suppression, wherein the drug inhibits hematopoietic progenitor cells and impairs erythroid differentiation

It is characterized by dose- and duration-dependent bone marrow suppression, wherein the drug inhibits hematopoietic progenitor cells and impairs erythroid differentiation Clinically, affected patients present with a progressive decline in hemoglobin concentrations and red blood cell counts, typically accompanied by marked macrocytosis In severe cases, this condition leads to profound symptomatic fatigue, pallor, and a reliance on red blood cell transfusions, serving as a specific indication for...

Clinically, affected patients present with a progressive decline in hemoglobin concentrations and red blood cell counts, typically accompanied by marked macrocytosis In severe cases, this condition leads to profound symptomatic fatigue, pallor, and a reliance on red blood cell transfusions, serving as a specific indication for intervention with erythropoiesis-stimulating agents